Physician profile
Eric R Lough
NPI 1437255916
$3,835.64
in general payments reported to CMS, 2019-2025
26 companies · $986 in 2025
The $986 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.14 · 2020: $123 · 2021: $608 · 2022: $682 · 2023: $626 · 2024: $725 · 2025: $986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,336.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $568.23 | 2021-2025 | Repatha, Repatha, Otezla |
| Glaxosmithkline, LLC. | $495.85 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Cleerly, INC. | $428.28 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Lilly USA, LLC | $425.19 | 2021-2024 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $413.38 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $317.05 | 2021-2024 | |
| Exact Sciences Corporation | $185.01 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $159.61 | 2021-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.93 | 2022-2023 | Spevigo, Jardiance, Synjardy |
| Abbvie INC. | $122.49 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $88.54 | 2023-2024 | |
| Novo Nordisk INC | $77.72 | 2024-2025 | Rybelsus, Ozempic |
| Kowa Pharmaceuticals America, INC. | $51.71 | 2021-2022 | |
| Corcept Therapeutics | $46.87 | 2025 | Korlym |
| Merck Sharp & Dohme LLC | $45.36 | 2021-2025 | Capvaxive |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $44.55 | 2024-2025 | Freestyle Libre 3 |
| Philips North America LLC | $38.94 | 2023 | |
| Boston Scientific Corporation | $36.86 | 2024 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $36.15 | 2025 | |
| Nestle Healthcare Nutrition INC. | $25.45 | 2021 | |
| Astellas Pharma US INC | $24.37 | 2023 | Veozah |
| Amarin Pharma, INC. | $18.52 | 2021 | |
| Sanofi Pasteur INC. | $18.20 | 2023 | |
| Shionogi INC | $17.32 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.12 | 2022 | |
| Idorsia Pharmaceuticals US INC | $12.94 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Lough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.